Teva Seeks To Revoke IP For J&J Unit's Schizophrenia Drug
Generic-drug giant Teva urged a London judge on Tuesday to revoke an extension on patent protections for a schizophrenia drug given to a Johnson & Johnson unit, arguing they never should...To view the full article, register now.
Already a subscriber? Click here to view full article